As previously communicated, Hakan Bjorklund, the current Chairman of the Board of Swedish Orphan Biovitrum AB (publ) (Sobi), has announced that he will not be available for re-election at the company's Annual General Meeting in 2023.

Sobi's Nomination committee proposes that the current Board member and Deputy Chairman Bo Jesper Hansen is elected as Chairman of the Board at the Annual General Meeting on 9 May 2023.

Bo Jesper Hansen has a long history with Sobi and predecessor companies. Bo Jesper served as CEO of Swedish Orphan International AB 1998-2010, is the co-founder of Swedish Orphan Biovitrum AB (publ) and served as Executive Chairman of the Board of Swedish Orphan Biovitrum AB (publ) 2010-2016. Bo Jesper Hansen has previously served on the Board of several listed companies and has extensive experience from several executive positions within research and development in the pharmaceutical industry.

Sobi

Sobi is a specialised international biopharmaceutical company transforming the lives of people with rare diseases. Providing sustainable access to innovative medicines in the areas of haematology, immunology and specialty care, Sobi has approximately 1,600 employees across Europe, North America, the Middle East and Asia. In 2021, revenue amounted to SEK 15.5 billion. Sobi's share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com, LinkedIn and YouTube.

Contact:

Tel: 46 8 697 20 00

(C) 2022 Electronic News Publishing, source ENP Newswire